Your fact-checks will appear here
Randomized trials and systematic reviews show penile traction devices (PTDs) can produce measurable length gains—typically about 1.5–2.2 cm over months—and reduce Peyronie’s curvature by roughly 10–25...
Clinical studies show penile traction devices (PTDs) can produce small but measurable length gains in men with Peyronie’s disease, men after prostatectomy, and some small studies in men with shortened...
FDA does clear some penile traction devices for *therapeutic* indications such as treating Peyronie’s disease and restoring length lost after urologic procedures, but the marketplace is full of produc...
Clinical evidence and regulatory guidance show penile traction devices (PTDs) can produce modest, sometimes durable length gains and improve curvature in men with Peyronie’s disease when used consiste...
Randomized trials and systematic reviews show penile traction devices (PTDs) can reduce curvature in Peyronie’s disease and in some studies preserve or modestly increase penile length (e.g., +1.6 cm v...
Penile traction devices (PTDs) are non‑surgical tools used mainly to treat Peyronie’s disease (PD) and to limit length loss or erectile dysfunction after prostate surgery; randomized and meta‑analytic...
Penile traction therapy (PTT) — the medically supervised use of traction devices — is generally described in the literature as tolerable with mostly mild, transient adverse effects in men treated for ...
Long‑term use of penile traction devices (PTDs) is generally reported as well tolerated, with most studies documenting mild, transient side effects such as discomfort, swelling, skin irritation, bruis...
Contemporary evidence shows two clusters of effective penile traction therapy (PTT) protocols: older-generation devices that required multi-hour daily wear (commonly ≥3–5 hours/day for several months)...
Sustained adherence to penile traction therapy (PTT) over 12–24 months appears to be driven less by a single demographic trait than by a mix of clinical state, device burden (time/cost), and early pat...
Multi‑hour penile traction protocols historically required 3–8 hours daily and produced substantial drop‑off in real‑world use; early studies flagged prolonged wear as a core reason patients did not p...
A small set of traction and implant products are commonly marketed for penile stretching or aesthetic enhancement, and several vendors explicitly claim FDA clearance or approval—most notably SizeGenet...
Randomized trials have mostly tested newer-generation penile traction devices (notably RestoreX and Penimaster PRO) against no‑intervention controls and have also explored shorter daily wear times (30...
A focused review of the supplied literature finds randomized, controlled trials of penile traction therapy (PTT) concentrated in two clinical populations—men with Peyronie’s disease (PD) and men after...
Urologists and the clinical literature recommend that penile traction devices be used with controlled, low-grade tension, careful attention to circulation and skin integrity, and under clinician guida...
Penile traction devices (PTDs) for Peyronie’s disease (PD) deliver modest, clinically meaningful reductions in curvature and small but inconsistent increases in penile length in selected patients, wit...
Medical societies and mainstream urology literature generally treat penile traction devices as a therapeutic option for specific medical conditions — especially Peyronie’s disease and post‑prostatecto...
Randomized trials and multiple prospective studies report that penile traction therapy (PTT) can produce measurable reductions in penile curvature (often ~18–21% in device trials) and modest gains in ...
Clinical research shows penile traction devices (PTDs) can meaningfully reduce curvature in Peyronie’s disease and produce modest, sometimes durable increases in stretched/flaccid length in selected s...